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Background: Bladder cancer results from complex interactions between many genetic and environment factors.
The polymorphism Ser326Cys in hOGG1 gene has been reported to be associated with bladder cancer in some
studies, though the results remain inconclusive. To explore this relationship of hOGG1 polymorphism and the
susceptibility for bladder cancer and the impact of smoking exposures, a cumulative meta-analysis was performed
in this study.
Methods: We extracted the data from the Pubmed database up to January 9, 2012 using the search phrases
“hOGG1, Ser326Cys polymorphism and bladder cancer”. Seven case–control studies were identified, including
2474 patients and 2408 controls. Four of them provided the analysis of smoking effects, with 1372 smokers and
947 non-smokers. The odds ratios (ORs) and associated 95 % confidence intervals (CIs) were calculated using
fixed- or random- effects models.
Results: Regarding the overall association between the hOGG1 326Cys allele and bladder cancer risk, the
meta-analysis did not reveal a significant effect in the additive model (OR: 1.06, 95 % CI: 0.96-1.26; p= 0.49),
the recessive genetic model (OR: 1.05, 95 % CI: 0.65-1.70; p= 0.85) or the dominant genetic model (OR: 1.07,
95 % CI: 0.87-1.32; p= 0.53). Similarly, no significant relationship was observed in the stratified analysis by ethnicity,
study design and Hardy-Weinberg equilibrium (all p> 0.05). In the non-smokers, however, hOGG1 326Cys allele
significantly increased the risk for bladder cancer and the ORs in the additive model, homozygote contrast and
recessive genetic model were 1.59 (p= 0.02), 2.53(p= 0.003) and 2.41(p= 0.0005), respectively. Nevertheless,
in the smoker subgroup, similar findings could not be found in all genetic models (all p> 0.05).
Conclusions: The association between the hOGG1 326Cys allele and bladder cancer was significant in non-smoker
population, while was non-detectable in common or smoker populations. This meta-analysis suggests that
the hOGG1 Ser326Cys polymorphism may be a risk factor for bladder cancer without exposure to smoking.
Further functional studies are needed to elucidate the gene polymorphism-bladder cancer relationship and
gene-environment interactions.Background
Bladder cancer remains one of the most common malig-
nant diseases around the world [1]. The occurrence of
bladder cancer resulted from many exogenous and endo-
genous factors, such as cigarette smoking, genetic back-
ground, and capability to repair damaged DNAs [2-7].* Correspondence: dr.cjliu@hotmail.com
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reproduction in any medium, provided the orIndeed, the DNA repairing systems, composed of many
DNA repair genes, play a critical role in removing damaged
genes, maintaining the genomic integrity and preventing
carcinogenesis. The human 8-oxoguanine glycosylase gene
(hOGG1) is such a commonly-studied DNA repair gene
[8,9]. It encodes the 8-oxoguanine DNA glycosylase, a key
enzyme in the removal of 8-oxodeoxyguanosines gener-
ated by oxidative stress and highly mutagenic. The poly-
morphisms in the hOGG1 genes may impair their abilities
to repair damaged genes, leading to genetic instability and
carcinogenesis [10].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the Ser326Cys polymorphism has received much atten-
tion in recent years. It is an amino acid substitution of
serine (Ser) with a cysteine (Cys) in exon 7 of hOGG1
gene [11,12], and the 326Cys allele reduces DNA repair
activity and increases the cancer risk [13-16]. In pursuit
of identifying an association between the Ser326Cys
polymorphism and bladder cancer risk, many studies
have been conducted. However, the results were incon-
sistent and even contradictory [17-23], presumably due
to the relatively small samples of individual studies, vari-
ous genetic background and possible selective bias.
Herein, we performed a meta-analysis on the previ-
ously reported studies, and investigated whether the
Ser326Cys polymorphism increases the bladder cancer
risk. Specifically, a stratified analysis was used to study
the Ser326Cys polymorphism-bladder cancer relation-
ship in general population, smoker and non-smokers,
and people with different ethnic backgrounds.
Materials and methods
Publication search
We searched all published studies (prior to January 9,
2012) investigating the association between the hOGG1
Ser326Cys polymorphism and bladder cancer risk in the
PubMed database. A literature search was conducted
using the search terms “human 8-oxoguanine DNA gly-
cosylase,” “hOGG1,” “OGG1,” “OGG,” “polymorphism,”
“genetic variation,” and “bladder cancer”. Review articles
and reference cited in the searched studies were exam-
ined to identify additional published articles. The listed
articles were assessed to determine whether they should
be included in the meta-analysis. For studies with over-
lapping data published by same investigators, only the
most recent or complete study was included. Conference
abstracts, case reports, editorials, review articles, and
letters were excluded. Studies included in the meta-
analysis were required to meet the following criteria:
1) an unrelated case–control design was used, 2) geno-
type frequency was available, and 3) there is an eval-
uation of the hOGG1 Ser326Cys polymorphism and
bladder cancer risk.
Data extraction
Two separate investigators reviewed and extracted data
from all of the eligible publications independently,
according to the inclusion and exclusion criteria listed
above. The following information was extracted from
each study: first author, year of publication, country of
study population, genotyping method, genotype fre-
quency, and the experimental design used to assess the
effect of the hOGG1 Ser326Cys polymorphism. Ethnic
backgrounds were categorized as either Caucasian or
Asian, and smoker status (smoker or non-smoker) wasadditionally recorded for the stratified analysis. Smokers
included current smokers and former smokers. Non-
smokers had never smoked.
Statistical analysis
The meta-analysis evaluated the overall association
between the hOGG1 Ser326Cys polymorphism and the
risk of bladder cancer using a number of methods. We
evaluated the risk of the additive model (326Cys allele
versus 326Ser allele), dominant model (Cys/Cys +Cys/
Ser versus Ser/Ser), recessive model (Cys/Cys versus
Cys/Ser + Ser/Ser) and the homozygote contrast (com-
parison of Cys/Cys versus Ser/Ser), respectively.
Hardy–Weinberg equilibrium (HWE) was tested using
the Chi-squared test and it was considered statistically
significant when p < 0.05. Sensitivity analysis was carried
out by including and excluding studies not in HWE [24].
The heterogeneity of these studies was tested by the Q
statistic [25] and was considered statistically significant
when p < 0.10. The heterogeneity was quantified by the
I2 metric, which is independent of the number of studies
used in the meta-analysis (I2 < 25%, no heterogeneity;
I2= 25–50%, moderate heterogeneity; I2 > 50%, extreme
heterogeneity) [26]. Publication bias was assessed by
a funnel plot using both funnel plots and Egger’s
linear regression test [27]. The combined odds ratio
(OR) was estimated using fixed effects (FE) models with
pheterogenity≥ 0.10, or random-effects (RE) models with
pheterogenity < 0.10 [28].
The overall association was measured by determining
the OR with a corresponding 95% confidence interval
(CI). The statistical significance of the overall OR was
determined using a Z-test; p < 0.05 was considered statis-
tically significant. Meta-analysis was performed using
the Review Manager 5.0 software and Egger’s test was
performed with STATA version 7.0.
Results
Study characteristics
After title and abstract screening, 10 case–control stud-
ies were found, however the studies by Kim et al.. [29]
only demonstrated the effect of hOGG1 Ser326Cys
on muscle invasion of bladder cancer, and the studies
by Wu et al. [30] and Huang et al. [21] , Gangwar
et al. [18] and Mittal [31] contained overlapped data.
The articles supplying more detailed information were
brought into the analysis [21,31]. Thus, a total of 7 pub-
lished studies met the inclusion criteria which included
a case–control study design and published genotype fre-
quencies. In all studies, the cases were histologically
confirmed, and the controls were free of bladder cancer
and matched for age and gender.
In total, 2474 bladder cancer cases and 2498 controls
were included in the meta-analysis. We conducted
Ji et al. BMC Cancer 2012, 12:335 Page 3 of 8
http://www.biomedcentral.com/1471-2407/12/335subgroup analysis classified by ethnicity, hospital-based
and HWE population. A summary of selected study
characteristics is listed in Table 1, and genotype, allele
frequencies and HWE information are shown in Table 2.
Among all studies, four studies assessed Caucasian
populations, including one from Spain [20], one from
the USA [21] and two from Turkey [22,23]. Three stud-
ies were used to assessed Asian populations, including
one from India [31], one from Korea [19] and one from
Japan [17]. Of the seven final studies, six were hospital-
based studies [19-23,31]. All studies but one [23] was
consistent with HWE, and the total controls were not in
HWE (P= 0.006).
Four of the seven eligible studies provided data on
smoker and non-smoker subjects [17,21,23,31]. Distribu-
tion of genotype and allele in the smoker versus non-
smoker groups is shown in Table 3. However, one of this
four studies only showed the data in dominant model
[31], while another did in recessive model [21]. These
studies were analyzed according to smoker status in dif-
ferent models.Main meta-analysis results
The heterogeneity results and the determined associ-
ation between the hOGG1 326Cys polymorphism and
bladder cancer risk are shown in Table 4. Overall results
showed that individuals carrying the hOGG1 326Cys al-
lele in the additive model did not have significantly
increased risk for bladder cancer compared to those car-
rying the 326Ser allele (OR: 1.06, 95% CI: 0.96-1.26;
p= 0.49) in the additive model. Similarly, no significant
difference in bladder cancer risk was found between the
patients with a Cys/Cys genotype and those with a Ser/
Ser genotype (OR 1.11, 95% CI = 0.74-1.66, p= 0.63) in
homozygote contrast. This was also the case for Cys/Cys
versus Ser/Cys + Ser/Ser in the recessive genetic model
(OR: 1.05, 95% CI: 0.65-1.70; p= 0.85) and for Cys/Cys +
Ser/Cys versus Ser/Ser in the dominant genetic model
(OR: 1.07, 95% CI: 0.87-1.32; p= 0.53) (Table 4 and
Figure 1).
These seven studies were analyzed by stratified anal-






Kim(2005) [19] Korea Asian PCR-RFLP N= 153 (62.9 ± 1
Karahalil (2006) [23] Turkey Caucasian PCR-RFLP N= 100 (mean a
Huang (2007) [21] USA Caucasian Taqman N= 696 (63.9 ± 1
Figueroa (2007) [20] Spain Caucasian Taqman N= 1150 (66 ± 1
Arizono (2008) [17] Japan Asian PCR-RFLP N= 251 (68.2 ± 1
Narter (2009) [22] Turkey Caucasian PCR-RFLP N= 83 (63.4 ± 11
Mittal (2011) [31] India Asian ARMS-PCR N= 212 (58.5 ± 1or Caucasians either in the additive model, the homo-
zygote contrast, the recessive model, or the dominant
model (all p > 0.05). Furthermore, no statistically signifi-
cant conclusions were found for hospital-based subjects
in the various statistical models (all p > 0.05). When
meta-analysis of studies in HWE was conducted, no sig-
nificant correlation was detected in any type of statistical
model, either (all p > 0.05).
Meta-analysis with different smoking status
In the stratified analysis of the effect of smoker status,
there were four studies discussing the interaction of
smoking behavior and hOGG1 Ser326Cys (Table 5). Due
to the missing data, three studies were included in dom-
inant or recessive model analysis, while two studies were
in additive model or homozygote contrast. Overall, there
were 1372 smokers (764 case and 608 controls) and 947
non-smokers (346 cases and 601 controls) included in
this part of meta-analysis. Two studies assessed Asian
population [17,31] and the other two assessed Caucasian
populations [21,23]. The samples in this analysis with
different smoking status were small, and then further
stratified analysis was not performed in this part of
meta-analysis.
In the non-smoker population, a significant association
was found between the hOGG1 326Cys allele and blad-
der cancer risk in the recessive model (OR: 2.41, 95% CI:
1.47-3.95; p= 0.0005). Similarly, this association was
found in the homozygote contrast (OR: 2.93, 95% CI:
1.43-5.99; p= 0.003) and the additive model (OR: 1.59,
95% CI: 1.08-2.32; p= 0.02) (Tables 5 and Figure 2).
However, no significant association was found in the
smoker population, between the hOGG1 326Cys allele
and bladder cancer risk (all p > 0.05). This finding sug-
gests a dominant effect of hOGG1 326Cys on bladder
cancer risk among the non-smokers.
Test of heterogeneity, sensitivity analysis and
publication bias
Significant heterogeneity between studies was observed
in some comparisons, and the detailed data were shown
in Table 4. An extreme heterogeneity between theseis
Controls (age) Design of
experiment
0.8 yrs) N = 153 (60.7 ± 11.8 yrs) Hospital-based
ge 60.2 yrs) N = 100 (age, sex matched controls) Hospital-based
1.1 yrs) N = 629 (age, sex matched controls) Hospital-based
0 yrs) N = 1149 (65 ± 10 yrs) Hospital-based
1.2 yrs) N = 251 (age-matched healthy controls) Population-based
.7 yrs) N = 45 (59.9 ± 9.71 yrs) Hospital-based
2.4 yrs) N = 250 (56.8 ± 10.8 yrs) Hospital-based




Cases n (%) Controls n (%) Cases n (%) Controls n (%)
Ser/Ser Ser/Cys Cys/Cys Ser/Ser Ser/Cys Cys/Cys Ser Cys Ser Cys
Kim (2005) [19] 37 (24.2%) 90 (58.8%) 26 (17.0%) 38 (24.8%) 70 (45.6%) 45 (29.4%) 164 (53.6%) 142 (46.4%) 146 (47.7%) 160 (52.3%) 0.30
Karahalil (2006) [23] 40 (40.4%) 47 (47.5%) 12 (12.1%) 62 (62.0%) 20 (20.0%) 18 (18.0%) 127 (64.1%) 71 (35.9%) 144 (72.0%) 56 (28.0%) <0.001
Huang (2007) [21] 375 (61.2%) 209 (34.1%) 29 (4.73%) 348 (58.0%) 216 (36.0%) 36 (6%) 959 (78.2%) 267 (21.8%) 912 (76.0%) 288 (24.0%) 0.75
Figueroa (2007) [20] 649 (59.7%) 383 (35.2%) 56 (5.15%) 596 (58.5%) 361 (35.5%) 61 (5.99%) 1681 (77.3%) 495 (22.7%) 1553 (76.3%) 483 (23.7%) 0.52
Arizono (2008) [17] 61 (24.3%) 107 (42.6%) 83 (33.1%) 67 (26.7%) 135 (53.8%) 49 (19.5%) 229 (45.6%) 273 (54.4%) 269 (53.6%) 233 (46.4%) 0.20
Narter (2009)[22] 37 (63.8%) 13 (22.4%) 8 (13.8%) 18 (50.0%) 18 (50.0%) 0 (0%) 87 (75.0%) 29 (25.0%) 54 (75.0%) 18 (25.0%) 0.08
Mittal (2011) [31] 92 (43.4%) 93 (43.9%) 27 (12.7%) 122 (48.8%) 111 (44.4%) 17 (6.8%) 277 (65.3%) 147 (34.7%) 355 (71.0%) 145 (29.0%) 0.21
















Table 3 hOGG1 Ser326Cys genotype frequency and distribution according to smoking status
First author [reference] Genotype
Cases n (%) Controls n (%)
Ser/Ser Ser/Cys Cys/Cys Ser/Ser Ser/Cys Cys/Cys
Smoker Karahalil (2006)[23] 14 (41.2%) 16 (47.1%) 4 (11.7%) 27 (62.8%) 9 (20.9%) 7 (16.3%)
Huang (2007) [21] 279 (62.7%) 166 a (37.3%) 183 (55.5%) 147a (44.5%)
Arizono (2008) [17] 42 (25.5%) 72 (43.6%) 51 (30.9%) 42 (26.6%) 83 (52.5%) 33 (20.9%)
Mittal (2011) [31] 107 b (89.2%) 13 (10.8%) 72 b (93.5%) 5 (6.49%)
Non-smoker Karahalil (2006) [23] 7 (53.8%) 4 (30.8%) 2 (15.4%) 38 (66.7%) 9 (15.8%) 10 (17.5%)
Huang (2007) [21] 96 (60.8%) 62 b (39.2%) 165 (59.4%) 113 b (40.6%)
Arizono (2008) [17] 19 (22.1%) 35 (40.7%) 32 (37.2%) 25 (26.9%) 52 (55.9%) 16 (17.2%)
Mittal (2011) [31] 75 a (84.3%) 14 (15.7%) 161 a (93.1%) 12 (6.94%)
a: As only the data of dominant model were available, these data were referred to the sum of Ser/Cys and Cys/Cys.
b: As only the data of recessive model were available, these data were referred to the sum of Ser/ Ser and Ser/Cys.
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Pheterogeneity = 0.02). Then, the random-effects (RE) mod-
els were used to evaluate the combined ORs when
necessary. Sensitivity analysis was performed both by
sequential removal (statistics of study removal) of indi-
vidual studies and cumulative statistics on the compari-
sons of worldwide subjects. The combined ORs of the
hOGG1 Ser326Cys polymorphism were not influencedTable 4 The main ORs of hOGG1 Ser326Cys polymorphisms in
Allele and genotype Populations




















a: The reference groups are the second genotypes.by either the addition or removal of any individual
study, such as the study from Narter et al. [22] with the
genotype distribution in the control group deviating
from HWE.
Funnel plots were performed to assess the publication
bias in this meta-analysis and showed a symmetrical in-
verse funnel shape (data not shown). The funnel results
suggested that the selection of publications was anthe meta-analysis
OR I2(%) Pheterogeneity Analysis
model
P
ns 1.06 (0.90, 1.26) 64% 0.01 Random 0.49
pulations 0.95 (0.85, 1.06) 30% 0.23 Fixed 0.38
tions 1.14 (0.82, 1.57) 75% 0.02 Random 0.44
d 1.00 (0.90, 1.11) 51% 0.07 Random 0.99
E 1.01 (0.91, 1.44) 65% 0.02 Random 0.83
ns 1.11 (0.74, 1.66) 65% 0.009 Random 0.63
pulations 0.87 (0.66, 1.16) 0% 0.41 Fixed 0.35
tions 1.34 (0.64, 2.83) 78% 0.01 Random 0.44
d 0.97 (0.65, 1.45) 54% 0.06 Random 0.89
E 1.12 (0.71, 1.79) 71% 0.004 Random 0.62
ns 1.05 (0.65, 1.70) 79% <0.0001 Random 0.85
pulations 0.85 (0.65, 1.21) 25% 0.26 Fixed 0.25
tions 1.26 (0.50, 3.17) 89% <0.0001 Random 0.62
d 0.89 (0.57, 1.38) 66% 0.01 Random 0.59
E 1.14 (0.67, 1.94) 81% <0.0001 Random 0.64
ns 1.07 (0.87, 1.32) 58% 0.03 Random 0.53
pulations 1.04 (0.74, 1.47) 75% 0.007 Random 0.82
tions 1.16 (0.91, 1.47) 0% 0.85 Fixed 0.23
d 1.07 (0.83, 1.36) 64% 0.02 Random 0.61
E 0.97 (0.86, 1.09) 0% 0.45 Fixed 0.59
Figure 1 Overall meta-analysis of the 326Cys allele in the recessive genetic model using a random-effect model.
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ciation between the hOGG1 Ser326Cys polymorphism
and bladder cancer.
Discussion
DNA damage generated by different carcinogenic agents
can be repaired primarily through base excision repair
(BER) pathway, composed of many DNA repair genes.
Common polymorphisms in DNA repair genes may alter
protein function and the possibility to repair damaged
DNA. Defects in DNA repair pathways may lead to gen-
etic instability and carcinogenesis [32,33]. The hOGG1
gene is a key gene in the BER pathway and DNA repair
process, and the Ser326Cys polymorphism is reported to
be a functional variation in the hOGG1 gene.
Since the original identification of the hOGG1
Ser326Cys polymorphism, a number of studies have
investigated the genetic effect of this polymorphism on
bladder cancer susceptibility. In the eligible studies, the
percentage of 326Cys allele was 0.523 in the Korean
population (n = 153), 0.464 in the Japanese population
(n = 251), and 0.290 in the Indian population (n = 250),
while it was 0.280, 0.240, 0.237 and 0.250, respectively,
for the Caucasian population in Turkey (n = 100), USATable 5 The ORs of hOGG1 Ser326Cys polymorphisms accord
Allele and genotype Populations
326Cys allele versus 326Ser allele (additive model) a Smoker subjects
Non-smoker subjects
Cys/Cys versus Ser/Ser (homozygote contrast) a Smoker subjects
Non-smoker subjec
Cys/Cys versus Cys/Ser + Ser/Ser
(recessive genetic model) a
Smoker subjects
Non-smoker subjec
Cys/Cys + Cys/Ser versus Ser/Ser
(dominant genetic model) a
Smoker subjects
Non-smoker subjects
a: The reference groups are the second genotypes.(n = 600), Spain (n = 1018) and Turkey (n = 36). Consid-
ering these inconsistent findings, we performed a meta-
analysis on these studies to quantify the available data
and generate a robust estimate of the effect of the
Ser326Cys polymorphism on bladder cancer. Meta-
analysis has been proved to be a powerful method from
a relatively large number of subjects [34,35].
In this study, we analyzed the data from seven avail-
able case–control studies. The results are conflicting
about the role of the hOGG1 Ser326Cys polymorphism
in relation to bladder cancer susceptibility. Three studies
found an increased risk for bladder cancer associated
with the 326Cys allele [17,23,31], two studies identified a
reduced risk [19,21], and the other two did not detect
the association between Ser326Cys polymorphism and
bladder cancer [20,22].
When all the eligible studies were pooled into analysis,
it failed to uncover any evidence that there was an asso-
ciation between the Ser326Cys polymorphism and blad-
der cancer susceptibility overall. No statistical evidence
was found in a recessive model, either in a dominant
model, an additive model or a homozygote contrast.
Moreover, the association of the Ser326Cys polymorph-
ism and bladder cancer could not be found in Asians oring smoker status
OR I2(%) Pheterogeneity Analysis
model
P
1.29 (0.97-1.71) 0% 0.64 Fixed 0.08
1.59 (1.08, 2.32) 0% 0.65 Fixed 0.02
1.46 (0.84, 2.56) 0% 0.66 Fixed 0.18
ts 2.93 (1.43, 5.99) 37% 0.21 Fixed 0.003
1.54 (1.00, 2.37) 0% 0.44 Fixed 0.05
ts 2.41 (1.47, 3.95) 0% 0.42 Fixed 0.0005
0.72 (0.26, 2.02) 87% 0.004 Random 0.53
1.58 (0.72, 3.50) 75% 0.02 Random 0.26
Figure 2 Overall meta-analysis of the Cys/Cys genotype in the recessive genetic model in the non-smoker population.
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based subpopulation or the population in HWE, no sig-
nificant conclusion were found. Taken together, it may
be concluded that hOGG1 Ser326Cys polymorphism
lacks association with bladder cancer risk in such com-
mon population.
Cigarette smoking is a major risk factor for bladder
cancer, and the association between smoking status and
bladder cancer risk remains a point of controversy.
Some studies have found that cigarette smoking was
more strongly associated with increased risk of invasive
bladder cancer than with low-grade superficial bladder
cancer [36]. Even among lifelong non-smoker popula-
tions, environmental tobacco smoke (ETS) exposure can
still be a risk factor for bladder cancer in women [24].
Therefore, meta-analysis was further performed among
smokers and non-smokers, to clarify the effect of smok-
ing behavior on this relationship. Interestingly, in non-
smokers, the analysis for combined data suggested a
remarked association between the hOGG1 Ser326Cys
polymorphism and bladder cancer risk. This association
was confirmed in the additive model, homozygote con-
trast and recessive genetic model, with the OR values
of 1.59 (p= 0.02), 2.93 (p= 0.003) and 2.41 (p= 0.005),
respectively. However, when the parallel analysis was
performed in smokers, no significantly statistical conclu-
sions were found in all genetic models (all p > 0.05).
It is well established that the carcinogenesis of bladder
cancer is a result of the interaction between environ-
mental factors and genetic background. Besides the role
of genetic variants, smoking behavior shows a major
effect on the bladder cancer susceptibility [4]. Smoking
status contributed to the heterogeneity in hOGG1
Ser326Cys estimates, since the frequencies of variant alleles
altered with different smoking behaviors [17,21,23,31].
Thus, the association of hOGG1 Ser326Cys polymorphism
and bladder cancer risk might alter under different
smoking status. Actually, when the eligible studies were
pooled into meta-analysis, a significant risk was shown
in the non-smoker subgroup, but not in the smoker
subgroup. Therefore, the genetic effect may be more
dominant in those who have not been exposed to anenvironmental risk factor. Notably, the results should be
interpreted with caution, since only limited studies are
included in this part of analysis.
The limitations of the present study include that 6 out
of the 7 studies in this meta-analysis are hospital-based
and only 1 is population-based, and the heterogeneity
and publication bias may exist due to the limited sample
size, and the variation in the genotyping methods and
experimental designs. Moreover, the real function of the
Ser326Cys polymorphism may have an effect only under
special conditions of cellular oxidative stress or tumor
types [37]. Among the common complicated population,
we could not detect significant association between
hOGG1 Ser326Cys and bladder cancer risk among over-
all studies, and Asian, Caucasian and hospital-based sub-
population. In addition, one study from Karahalil et al.
[23] was not in HWE among the controls. But, the OR
was not substantially altered when the subpopulation in
HWE was pooled. It might due to that the weight of this
study was only 5 % and is unlikely to influence much of
our results. Moreover, the combined ORs of the hOGG1
Ser326Cys polymorphism were not influenced by any in-
dividual study. All of these suggest that well-designed
and prospective studies with larger sample sizes should
be conducted to clarify the role of hOGG1 Ser326Cys
polymorphism in bladder carcinogenesis.Conclusions
In summary, our meta-analysis suggests the Ser326Cys
polymorphism lacks association with bladder cancer risk
in common population, but specifically increases the
susceptibility for non-smoker populations. Further stud-
ies are needed, especially to investigate the effect of the
gene-environment interaction.
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